Maintenance of Healed Erosive Esophagitis: A Randomized Six-Month Comparison of Esomeprazole Twenty Milligrams With Lansoprazole Fifteen Milligrams

Clinical Gastroenterology and Hepatology

Volumn 4, Issue 7, 2006, Pages 852-859

  DeVault, Kenneth R ^a   Johanson, John F ^b   Johnson, David A ^c   Liu, Sherry ^d   Sostek, Mark B ^d  

^a MAYO CLINIC   (United States)

^b Rockford Gastroenterology Associates   (United States)

^c EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^d ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; ENDOSCOPY; ESOPHAGOGASTRODUODENOSCOPY; FEMALE; FOOD REGURGITATION; GASTRITIS; GASTROESOPHAGEAL REFLUX; HEADACHE; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; REMISSION; STATISTICAL SIGNIFICANCE; SYMPTOM; UNITED STATES; UNSPECIFIED SIDE EFFECT;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; AGED; ANTI-ULCER AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ENDOSCOPY, DIGESTIVE SYSTEM; ESOPHAGITIS, PEPTIC; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; TREATMENT OUTCOME;

EID: 33745739304     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2006.03.006     Document Type: Article

References (23)

1. Spechler S.J. Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion 51 Suppl 1 (1992) 24-29
2. Carlsson R., Dent J., Watts R., et al. Gastro-oesophageal reflux disease in primary care. an international study of different treatment strategies with omeprazole. Eur J Gastoenterol Hepatol 10 (1998) 119-124
3. Chiba N. Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis. a systematic overview. Can J Gastroenterol 11 Suppl B (1997) 66B-73B
4. Dent J., Brun J., Fendrick A.M., et al. An evidence-based appraisal of reflux disease management. the Genval Workshop Report. Gut 44 Suppl 2 (1999) S1-S16
5. DeVault K.R., and Castell D.O. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 100 (2005) 190-200
6. Holloway R.H., Dent J., Narielvala F., et al. Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis. Gut 38 (1996) 649-654
7. Andersson T., Röhss K., Bredberg E., et al. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment Pharmacol Ther 15 (2001) 1563-1569
8. Miner Jr. P., Katz P.O., Chen Y., et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole. a five-way crossover study. Am J Gastroenterol 98 (2003) 2616-2622
9. Rohss K., Lind T., and Wilder-Smith C. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. Eur J Clin Pharmacol 60 (2004) 531-539
10. Castell D.O., Kahrilas P.J., Richter J.E., et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 97 (2002) 575-583
11. Fennerty M.B., Johanson J., Hwang C., et al. Efficacy of esomeprazole 40 mg vs lansoprazole 30 mg for healing moderate to severe erosive oesophagitis. Aliment Pharmacol Ther 21 (2005) 455-463
12. Labenz J., Armstrong D., Lauritsen K., et al. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis. the EXPO study. Aliment Pharmacol Ther 21 (2005) 739-746
13. Lauritsen K., Devière J., Bigard M.-A., et al. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis. Metropole study results. Aliment Pharmacol Ther 17 (2003) 333-341
14. Lundell L.R., Dent J., Bennett J.R., et al. Endoscopic assessment of oesophagitis. clinical and functional correlates and further evaluation of the Los Angeles classification. Gut 45 (1999) 172-180
15. Kahrilas P.J., Falk G.W., Johnson D.A., et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients. a randomized controlled trial. Aliment Pharmacol Ther 14 (2000) 1249-1258
16. Richter J.E., Kahrilas P.J., Johanson J., et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis. a randomized controlled trial. Am J Gastroenterol 96 (2001) 656-665
17. Nexium (esomeprazole magnesium) prescribing information. AstraZeneca LP, Wilmington, DE, December 2004. Available at: http://www.astrazeneca-us.com/pi/Nexium.pdf. Accessed June 23, 2005.
18. Prevacid (lansoprazole) prescribing information. TAP Pharmaceuticals Inc, Lake Forest, IL, July 2004. Available at: http://www.prevacid.com/prescribing_information.asp. Accessed June 23, 2005.
19. Protonix (pantoprazole sodium) prescribing information. Wyeth Pharmaceuticals, Inc, Collegeville, PA, December 2004. Available at: http://www.wyeth.com/content/ShowLabeling.asp?id=135. Accessed June 23, 2005.
20. AcipHex (rabeprazole sodium) prescribing information. Eisai Inc, Teaneck, NJ, August 2003. Available at: http://www.aciphex.com/pdf/aciphexpi.pdf. Accessed June 23, 2005.
21. Prilosec OTC (Procter & Gamble). Product information. Available at: http://www.thomsonhc.com/pdrel/librarian. Accessed June 15, 2005.
22. Ronkainen J., Aro P., Storskrubb T., et al. High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population. a Kalixanda study report. Scand J Gastroenterol 40 (2005) 275-285
23. Ecclissato C., Carvalho A.F., Ferraz J.G., et al. Prevalence of peptic lesions in asymptomatic, healthy volunteers. Dig Liver Dis 33 (2001) 403-406